1859 Inc. Launches With $40 Million Series A To Industrialize New Medicine Discovery By Combining Artificial Intelligence And Empirical Screening Data At Scale
1859 Inc. Launches With $40 Million Series A To Industrialize New Medicine Discovery By Combining Artificial Intelligence And Empirical Screening Data At Scale
02/07/22, 2:00 PM
Location
san diegoMoney raised
$40 million
Industry
science and engineering
data and analytics
health care
Round Type
series a
1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale to discover new small molecule medicines for emerging disease targets, launched today and announced the close of a highly successful Series A funding round of $40 million led by experienced life science investors Northpond Ventures and OMX Ventures. Existing investors, FusionX Ventures and Vertical Venture Partners also joined the round. The venture funds will support the development of new capabilities, and the scaling and advancement of preclinical discovery programs building upon a base of 16 pharmaceutical, biotech and academic partners.
Company Info
Location
san diego, california, united states
Additional Info
We are accelerating drug discovery to deliver treatments to patients faster.
Our powerful engine integrates combinatorial chemistry, pico-scale activity-based screening, and AI, generating millions of empirical datapoints every week to evolve our models.
This enables our biologists and medicinal chemists to discover novel small molecule therapeutics rapidly.